Sonnet BioTherapeutics shareholders approve proposed business merger with Hyperliquid Strategies Inc.
Foresight News reported that, according to a press release from Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), Sonnet announced that its shareholders approved the proposed business combination with Hyperliquid Strategies Inc (HSI) and Rorschach I LLC, among other matters, at a special meeting. The final voting results will be submitted to the U.S. Securities and Exchange Commission (SEC) on Form 8-K. Sonnet is a biotechnology company focused on oncology, with a proprietary biologics innovation platform called FHAB (Fully Human Albumin Binding). This technology uses human serum albumin (HSA) to deliver drugs to target tissues, aiming to improve the safety and efficacy of immunomodulatory biologics.
According to the proposed business combination transaction, the Form S-4 registration statement previously filed by HSI became effective on October 27, which includes a proxy statement for use by Sonnet shareholders and will also serve as HSI's prospectus. Upon completion of the proposed business combination, HSI's securities are expected to be listed on Nasdaq.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
MocaPortfolio announces details of ME token sale, with a total allocation of 2.195 million ME
Uniswap proposal set for voting, UNI largest short positions liquidated by over 40%
Settlement system 21X integrates Stellar network to expand multi-chain deployment
753 bitcoins transferred from an unknown wallet to Antpool
